Daily Reporter

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More



Off-label therapies: what is their future?

Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge. Advances in cancer research and the regulatory approval of new agents do not usually…

Read More



INVICTUS trial: positive results for patients with GIST

Ripretinib as fourth-line therapy showed to improve progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) in the phase III INVICTUS trial presented today. According to Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland,…

Watch Here